In search of new strategies against life-threatening tuberculosis infections, a team from the Technical University of Munich (TUM), as well as Harvard University and Texas A&M University in the USA have found a new ally. They discovered a substance that interferes with the mycomembrane formation of the bacterium. It is effective even in low concentrations and when combined with known antibiotics their effectiveness is improved by up to 100-fold.
Among the greatest challenges when treating life-threatening tuberculosis infections is the increasing resistance to antibiotics. But the pathogen itself also makes the life of doctors difficult: its dense mycomembrane hampers the effect of many medications. A team of scientists headed by Stephan A. Sieber, Professor of Organic Chemistry at TU Munich, has discovered a substance that perturbs the formation of this membrane significantly.
The mycomembrane of the tuberculosis pathogen Mycobacterium tuberculosis consists of a lipid double layer that encapsulates the cell wall, forming an exterior barrier. Structural hallmarks are mycolic acids, branched beta-hydroxy fatty acids with two long hydrocarbon chains. The team hypothesizes that similarly structured beta lactones could “mask” themselves as mycolic acid to enter the mycolic acid metabolic pathways and then block the decisive enzymes.
In the context of an extensive search, the interdisciplinary team of scientists hit the bullseye with the beta lactone EZ120. It does indeed inhibit the biosynthesis of the mycomembrane and kills mycobacteria effectively. Using enzyme assays and mass spectroscopy investigations, Dr. Johannes Lehmann, a researcher at the Chair of Organic Chemistry II at TU Munich, demonstrated during his doctoral work that the new inhibitor blocks especially the enzymes Pks13 and Ag85, which play a key role in the development of mycomembranes.
EZ120 is effective even in low doses, easily passes the mycomembrane and exhibits only low toxicity to human cells. The combined application of this substance with known antibiotics showed a synergistic effect leading to significantly increased effectiveness.”Vancomycin, a common antibiotic, and EZ120 work together very well,” says Prof. Sieber, who heads the Chair of Organic Chemistry II. “When used together, the dose can be reduced over 100-fold.
“The scientists suspect that disrupting the mycomembrane enables antibiotics to enter the bacteria more easily. This is a new mode of action and might be a starting point for novel tuberculosis therapies.
Learn more: Double strike against tuberculosis
The Latest on: Tuberculosis
- Specific HIV and tuberculosis medications decrease risk of death in adults with drug-resistant TBon August 10, 2020 at 10:32 pm
After looking at the health records of over 10,000 patients with both HIV and multidrug resistant Tuberculosis (TB) in over 20 different countries, researchers at the Perelman School of Medicine at ...
- Tuberculosis vaccine may help protect against COVID-19: Israeli researchon August 10, 2020 at 12:09 pm
Israeli researchers have found that vaccinations against tuberculosis may provide additional protection against COVID-19, Ben Gurion University (BGU) in southern Israel said Monday.
- Tuberculosis vaccine research could benefit the elderly and diabeticson August 10, 2020 at 12:01 pm
A study of older mice with type 2 diabetes has yielded highly promising results for researchers investigating potential new vaccines for tuberculosis (TB).
- Research suggests greater access to specific HIV and tuberculosis medications is neededon August 10, 2020 at 6:09 am
A specific combination of HIV and TB treatments, difficult to obtain in certain parts of the world, decreased mortality risk for patients with HIV and multidrug-resistant TB.
- Tuberculosis Testing Market 2020 By Industry Size Estimation, Industry Share, Future Demand, Dynamics, Drivers, Research Methodology By 2024on August 10, 2020 at 4:59 am
Global "Tuberculosis Testing Market" report exhibits a pin-point breakdown of Industry dependent on type, applications, ...
- Prevalence of HIV infection and bacteriologically confirmed tuberculosis among individuals found at bars in Kampala slums, Ugandaon August 10, 2020 at 2:12 am
Individuals found at bars in slums have several risk factors for HIV and tuberculosis (TB). To determine the prevalence of HIV and TB among individuals found at bars in slums of Kampala, Uganda, we ...
- Tuberculosis Diagnostic Market Growth, Recent Trends by Regions, Type, Application and Geographical Analysis to 2026on August 7, 2020 at 5:05 am
Final Report will add the analysis of the impact of COVID-19 on this industry” The "Tuberculosis Diagnostic Market" ...
- World film premiere: Death of cell infected with tuberculosison August 6, 2020 at 9:13 am
Probably every fourth person harbors tuberculosis bacteria in their body, although only five to ten percent of the infected population actually get sick. People who contract the illness need to take ...
- NYT: Tuberculosis, HIV, Malaria are spreading...on August 5, 2020 at 4:36 pm
Tuberculosis, HIV, Malaria are spreading", a CBSN video on CBSNews.com. View more CBSN videos and watch CBSN, a live news stream featuring original CBS News reporting.
- Tackling Tuberculosis with AI: Novel TBMeld® Platform to Transform Research in the Prevention and Treatment of Tuberculosison July 31, 2020 at 8:35 pm
InveniAI announces partnership with the Mueller Health Foundation (MHF) to create a first of its kind AI-driven platform to be used for the discovery, tracking, and evaluation of 1) novel TB vaccines, ...
via Google News and Bing News